SIGN UPLog In

Last deal

$135M

Amount

Series A

Stage

14.02.2024

Date

2

all rounds

$150M

Total amount

General

About Company
The company develops non-opioid therapies for chronic pain, providing patients with addiction-free pain management options.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Latigo Bio

founded date

01.01.2018

Number of employees

1-10

Last funding type

Series A

IPO status

Private

Description

The drug discovery company utilizes unique insights to target therapeutics across the blood-nerve barrier, offering patients a differentiated approach to pain management that does not lead to addiction, dependence, or tolerability issues.
Contacts